Navigation Links
Uroplasty Highlights Results From Clinical Study on Macroplastique(R) for the Treatment of Stress Urinary Incontinence
Date:1/13/2009

atients and a control group of 125 that received a commercially available bioabsorbable urethral bulking agent for one year.

  • Of the 247 study patients in the study, the average age was approximately 61 years, 73% were post-menopausal, about one fourth had previous failed urinary incontinence surgery, and over 50% had hysterectomies.
  • In the Macroplastique group, the dry/cure rate was 36.9% compared to 24.8% in the control group.
  • After 12 months, 61.5% of Macroplastique patients had improved 1 Stamey grade (a measure of incontinence improvement) compared to 48% of control patients.
  • The Macroplastique group's one-hour pad weight decrease was 25.4 ml from baseline compared to 22.8 ml for the control group.
  • Mean improvement for Macroplastique patients, in Urinary Incontinence Quality of Life Scores (I-QOL), was 28.7 compared to 26.4 for control patients.

An abstract of the study is available at: http://www.jurology.com/article/S0022-5347(08)02452-X/abstract

"I am pleased to have collaborated with leading Urologists and Urogynecologists throughout North American in conducting this study of Macroplastique," said Gamal Ghoniem, MD, Head, section of Voiding Dysfunction, Female Urology and Reconstruction and Chairman of Medical Education at Cleveland Clinic Florida and the study's primary author. "After treatment with Macroplastique, we measured clinical improvement to a patient's condition using a number of widely accepted outcome measures including cure rates, pad weight tests, and quality of life questionnaires. As a result, this study provides strong scientific evidence of the effectiveness of Macroplastique for the treatment of stress urinary incontinence.

In addition to Dr. Ghoniem, the study cred
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Uroplasty Enrolls First Patients in Urgent(R) PC Clinical Trial
2. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
3. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
4. Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects
5. Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
6. September 2008 Mayo Clinic Health Letter Highlights Cataract Removal, Severe Headache and Dual Energy X-Ray Imaging
7. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
8. August 2008 Mayo Clinic Womens HealthSource Highlights Avoiding Blood Pressure Increase at Menopause, Healthful Benefits of Dark Chocolate and Scheduling a Colorectal Exam
9. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
10. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
11. June 2008 Mayo Clinic Womens HealthSource Highlights Shingles Vaccine for Pain Prevention, Tips to Avoid Antibiotic Resistant Infections, and Benefits of Broad Genetic Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Lilly and Company (NYSE: LLY ) and AstraZeneca ... entered into a clinical trial collaboration to evaluate the ... checkpoint inhibitor, MEDI4736, in combination with CYRAMZA ® ... planned study will assess the combination as a treatment ... Phase I study is expected to establish the safety ...
(Date:5/28/2015)... INDIANAPOLIS , May 28, 2015  Eli Lilly and ... of its previously announced cash tender offer for up to ... debt securities. Holders of notes who tendered, and ... p.m., New York City time, on ... accepted for purchase by Lilly, are eligible to receive the ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... Dec. 16, 2010 Solta Medical, Inc. (Nasdaq: ... tightening and a market leader in aesthetic skin treatments, today ... revolutionary Thermage and Fraxel devices that have helped to build ... device industry. The milestone reflects how much the ...
... 2010 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... today announced that it has provided notice of voluntary ... Business Financial Services Inc. and Silicon Valley Bank.  The ... on the facility, including interest and other fees payable ...
Cached Medicine Technology:Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 2Solta Medical Ships One Millionth Tip for Thermage and Fraxel Devices 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 2Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 3Poniard Pharmaceuticals Announces Plan for Voluntary Prepayment of Term Loan and Transfer to Nasdaq Capital Market 4
(Date:5/30/2015)... May 30, 2015 Twelve of the ... by their peers as the 2015 Giants of ... at the Chicago Illuminating Company last night. The awardees ... oncologists for landmark achievements in translational research, gene therapy, ... course of cancer treatment. , Honorees were introduced and ...
(Date:5/30/2015)... You've probably heard that using cotton swabs to clean the ... found a better way to remove ear wax? Luckily, a ... need. , They developed SUNDENG EAR CLEANER to ease the ... from the ears. What's more, it is safer and more ... today for children and adults of all ages. As such, ...
(Date:5/30/2015)... 30, 2015 Thousands of aesthetic industry ... Meeting, sponsored by the American Society for Aesthetic Plastic ... hand was Zeltiq, the parent company of one of ... With blazing growth, the one-of-a-kind device just sold ... Zeltiq is currently in the news for gaining the ...
(Date:5/30/2015)... The results of a 40+ year study in ... to cause mesothelioma, regardless of the volume of exposure. ... Surviving Mesothelioma website. , The study conducted by ... found that, among the 138 cases of mesothelioma that ... of them happened at plants that had, at some ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
Breaking Medicine News(10 mins):Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 2Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 3Health News:OncLive’s 2015 Giant of Cancer Care™ Awards Announced 4Health News:Improved Ear Hygiene Tool Invented by InventHelp Clients (KSC-952) 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 2Health News:Dr. Paul Vitenas Meets with Zeltiq President and CEO in Montreal 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2
... unlikely to be caused by a decrease in mammography screening, ... Journal of the National Cancer Institute . It is ... , There has been a recent, rapid decline in ... Initiative study found that hormone therapy was associated with an ...
... B: apo A-I ratio is not a better predictor ... that include total cholesterol and HDL-C, according to a ... Current risk-prediction instruments and guidelines for coronary heart disease ... (LDL-C), total cholesterol, or both for CHD risk assessment. ...
... can diagnose venous thromboembolic disease (VTED) in cancer patients ... the thorax, abdomen, and pelvis which are regularly done ... according to a recent study conducted by radiologists at ... , Venous thromboembolic disease can be fatal if left ...
... warfarin) and antiplatelet drugs (e.g., acetylsalicylic acid) are ... diseases. In this study, Joseph Delaney MSc, Dr. ... in 4,028 cases with a diagnosis of gastrointestinal ... Kingdom. They documented a 46-fold increase in the ...
... Spirometry testing is a widely accepted and encouraged ... new research shows that it is not used nearly ... CHEST, the peer-reviewed journal of the American College of ... patients with a COPD diagnosis ever received spirometry testing. ...
... in a nursing home or take medication to lower ... following hospitalization for heatstroke, according to a study posted ... issue of Archives of Internal Medicine, one of the ... online today found that being confined to bed, not ...
Cached Medicine News:Health News:Drop in breast cancer incidence linked to hormone use, not mammograms 2Health News:Use of certain lipid measures not more effective in predicting coronary heart disease 2Health News:Study says COPD testing is not measuring up 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 2Health News:Study, meta-analysis examine factors associated with death from heatstroke 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: